Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG.

Arch Gen Psychiatry. 2005 Apr;62(4):435-41.

2.

The effect of a three-tier formulary on antidepressant utilization and expenditures.

Hodgkin D, Parks Thomas C, Simoni-Wastila L, Ritter GA, Lee S.

J Ment Health Policy Econ. 2008 Jun;11(2):67-77.

PMID:
18509214
3.

The effect of incentive-based formularies on prescription-drug utilization and spending.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.

N Engl J Med. 2003 Dec 4;349(23):2224-32.

4.

Employer drug benefit plans and spending on prescription drugs.

Joyce GF, Escarce JJ, Solomon MD, Goldman DP.

JAMA. 2002 Oct 9;288(14):1733-9. Erratum in: JAMA 2002 Nov 20;288(19):2409.

PMID:
12365957
5.

Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.

Klepser DG, Huether JR, Handke LJ, Williams CE.

J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77.

6.
7.

The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees.

Huskamp HA, Deverka PA, Landrum MB, Epstein RS, McGuigan KA.

Health Serv Res. 2007 Oct;42(5):1926-42.

8.

Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.

Hodgkin D, Horgan CM, Quinn AE, Merrick EL, Stewart MT, Leslie LK.

Clin Ther. 2014 Dec 1;36(12):2034-46. doi: 10.1016/j.clinthera.2014.09.019. Epub 2014 Nov 14.

9.

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Motheral B, Fairman KA.

Med Care. 2001 Dec;39(12):1293-304.

PMID:
11717571
10.
11.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

12.

Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease.

Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ.

J Manag Care Pharm. 2003 Mar-Apr;9(2):123-33.

14.

Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.

Shirneshan E, Kyrychenko P, Matlin OS, Avila JP, Brennan TA, Shrank WH.

J Clin Pharm Ther. 2016 Feb;41(1):64-9. doi: 10.1111/jcpt.12349. Epub 2016 Jan 18.

PMID:
26778812
16.

Incentive formularies and changes in prescription drug spending.

Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, Newhouse JP.

Am J Manag Care. 2007 Jun;13(6 Pt 2):360-9.

17.
18.

Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.

Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL.

Pharmacoeconomics. 2011 Jul;29(7):621-35. doi: 10.2165/11584590-000000000-00000.

PMID:
21473655
19.

Controlling prescription drug expenditures: a report of success.

Miller DP, Furberg CD, Small RH, Millman FM, Ambrosius WT, Harshbarger JS, Ohl CA.

Am J Manag Care. 2007 Aug;13(8):473-80.

20.

Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.

Tseng CW, Brook RH, Keeler E, Mangione CM.

JAMA. 2003 Jul 9;290(2):222-7.

Supplemental Content

Support Center